Klinikum Frankfurt Hoechst GmbH
- Address
- lock Available on a paid plan
Klinikum Frankfurt Hoechst GmbH - Breast Cancer Research Center
Klinikum Frankfurt Hoechst GmbH is a leading clinical research institution with extensive expertise in oncology clinical trials, particularly focusing on breast cancer therapeutics. The center demonstrates comprehensive capabilities in evaluating novel treatment approaches across all breast cancer subtypes, from early-stage disease through advanced and metastatic presentations.
- Triple-negative breast cancer (TNBC) neoadjuvant and adjuvant immunotherapy trials
- Hormone receptor-positive/HER2-negative breast cancer with targeted therapies including CDK4/6 inhibitors and PARP inhibitors
- HER2-positive breast cancer studies evaluating antibody-drug conjugates and personalized treatment strategies
- Gastrointestinal malignancies including gastric and gastroesophageal junction adenocarcinomas, and ovarian cancer research
The center's portfolio includes pivotal phase II and III studies investigating precision medicine approaches with biomarker-driven patient selection, including germline BRCA mutations, PIK3CA alterations, and NPM1-mutated acute myeloid leukemia. Their research encompasses innovative combination strategies with immunotherapies, targeted agents, and chemotherapy, with particular emphasis on adjuvant and neoadjuvant treatment optimization to improve disease-free survival and overall outcomes in high-risk patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 57 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 56 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Frankfurt Hoechst GmbH
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke | Shionogi B.V. | Phase II | Not Yet Recruiting | Feb 2024 | Jun 2026 |
IMP list
lock Showing 1 of 57 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 3 | Unknown | 2019-06-14 | 2025-03-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.